D.E. Shaw & Co
EIGR

D.E. Shaw & Co’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

D.E. Shaw & Co’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,550
Closed -$54.9K – 5008
2022
Q4 		$54.9K Sell
1,550
-1,857
-55% -$223K ﹤0.01% 4429
2022
Q3 		$770K Sell
3,407
-5,153
-60% -$1.27M ﹤0.01% 3775
2022
Q2 		$1.62M Sell
8,560
-2,642
-24% -$533K ﹤0.01% 3250
2022
Q1 		$2.79M Buy
11,202
+10,236
+1,060% +$1.62M ﹤0.01% 2980
2021
Q4 		$150K Buy
+966
New +$187K ﹤0.01% 4968
2021
Q1 		– Sell
-777
Closed -$286K – 4576
2020
Q4 		$286K Sell
777
-2,436
-76% -$699K ﹤0.01% 3617
2020
Q3 		$785K Sell
3,213
-4,047
-56% -$1.26M ﹤0.01% 2995
2020
Q2 		$2.09M Buy
7,260
+4,746
+189% +$1.4M ﹤0.01% 2381
2020
Q1 		$513K Buy
2,514
+663
+36% +$211K ﹤0.01% 3197
2019
Q4 		$827K Buy
1,851
+1,369
+284% +$486K ﹤0.01% 3111
2019
Q3 		$148K Buy
+482
New +$157K ﹤0.01% 3665
2015
Q2 		– Sell
-57
Closed -$489K – 3910
2015
Q1 		$489K Buy
57
+14
+33% +$122K ﹤0.01% 3056
2014
Q4 		$375K Buy
43
+1
+2% +$5.8K ﹤0.01% 3519
2014
Q3 		$196K Buy
+42
New +$222K ﹤0.01% 3897

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's EIGR Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2023, closing a stake of 1,550 shares — an estimated $54.9K sold.

D.E. Shaw & Co first reported a position in EIGR in Q3 2014 and held it in 14 quarters. The position peaked at $2.79M in Q1 2022. 71 funds tracked by Wall St. Rank hold EIGR as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,550 Eiger BioPharmaceuticals, Inc. shares in Q1 2023, an estimated $54.9K.
  • D.E. Shaw & Co first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2014 and held it in 14 quarters.
  • D.E. Shaw & Co's Eiger BioPharmaceuticals, Inc. position peaked at $2.79M in Q1 2022.
  • 71 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.